MRPL7 Antibody

What is MRPL7 and what cellular functions does it perform?

MRPL7 (Mitochondrial Ribosomal Protein L7) is a component of the large subunit of mitochondrial ribosomes (mitoribosomes). It plays a critical role in mitochondrial protein synthesis by forming a ribosomal stalk with MRPL12, which is essential for the recruitment of translation factors to the mitoribosome . The protein is also referred to as bL27 in the updated nomenclature for mitoribosomal proteins. MRPL7 contains a mitospecific domain that supports mitochondrial function, particularly in the adaptation from fermentative to respiratory metabolism .

Functionally, MRPL7 is involved in the assembly and stability of the large mitoribosomal subunit, which is crucial for the translation of mitochondrial DNA-encoded proteins. These proteins are primarily components of the oxidative phosphorylation (OXPHOS) system, including subunits of complexes like cytochrome c oxidase (COX) and the cytochrome bc1 complex . Truncation experiments with the C-terminal domain of MRPL7 have demonstrated its importance in supporting normal respiratory-based growth and metabolic adaptation.

What are the key differences between MRPL7 and similar proteins like MRPS7 and MRP7?

Despite similar nomenclature, MRPL7, MRPS7, and MRP7 are distinct proteins with different cellular functions:

MRPL7 is part of the large mitoribosomal subunit and forms a stalk with MRPL12 , while MRPS7 (also known as bMRP-27a, MRP-S7, S7mt) is a component of the small mitoribosomal subunit . In contrast, MRP7 (ABCC10) is completely unrelated to mitochondrial ribosomes and functions as a transmembrane efflux pump that confers resistance to various anticancer drugs and antiviral agents .

What are the common applications of MRPL7 antibodies in mitochondrial research?

MRPL7 antibodies are valuable tools in multiple applications for mitochondrial research:

• Western Blotting: Detection of MRPL7 protein levels in mitochondrial extracts to assess mitoribosome integrity and abundance.

• Immunoprecipitation: Investigation of MRPL7's interaction with other mitoribosomal proteins, particularly MRPL12 and components of the ribosomal stalk.

• Immunofluorescence: Visualization of mitoribosome distribution and dynamics within mitochondria.

• Sucrose gradient analysis: Using antibodies to track the presence of MRPL7 in different mitoribosomal assembly intermediates.

• Blue Native-PAGE: Analysis of mitoribosome complex integrity when combined with immunodetection.

These applications are particularly valuable for studying mitochondrial translation defects, respiratory chain assembly, and adaptations between fermentative and respiratory metabolism .

How are MRPL7 antibodies typically validated for research applications?

Proper validation of MRPL7 antibodies typically includes multiple complementary approaches:

• Western blot analysis: Testing against wild-type samples versus MRPL7 knockdown or knockout controls to confirm specificity. Antibodies should detect a band at the predicted molecular weight of approximately 31 kDa.

• Immunoreactivity across species: Validation across relevant model organisms to confirm cross-reactivity or species specificity based on evolutionary conservation.

• Subcellular fractionation: Confirming enrichment in mitochondrial fractions rather than other cellular compartments.

• Application-specific validation: For each application (western blot, immunoprecipitation, immunofluorescence), specific validation parameters should be established, including optimal dilutions and conditions.

• Epitope mapping: Determining which region of MRPL7 the antibody recognizes, which is particularly important when studying truncated variants as seen in studies with MRPL7 C-terminal deletions .

The importance of proper validation is highlighted by the observation that some monoclonal antibodies may not recognize truncated forms of MRPL7 if their epitopes are located in the deleted regions .

How can MRPL7 antibodies be used to investigate mitoribosome assembly defects?

MRPL7 antibodies can provide valuable insights into mitoribosome assembly defects through several methodological approaches:

• Sucrose gradient centrifugation coupled with immunoblotting: This approach allows researchers to analyze the distribution of MRPL7 across different mitoribosomal assembly intermediates and mature complexes. Abnormal distribution patterns can indicate assembly defects.

• Proximity labeling coupled with immunoprecipitation: By using MRPL7 antibodies in conjunction with proximity labeling techniques (BioID or APEX), researchers can identify proteins in close proximity to MRPL7 during different stages of mitoribosome assembly.

• Pulse-chase experiments with immunoprecipitation: This approach can track the incorporation of MRPL7 into nascent mitoribosomes over time.

• Comparative analysis across mutant strains: As demonstrated in studies with truncated MRPL7 variants, antibodies can be used to assess how mutations affect incorporation into mitoribosomes and subsequent impacts on translation .

• Blue Native-PAGE with 2D separation: This approach can separate intact mitoribosomal complexes followed by denaturation and immunodetection of MRPL7 to identify assembly intermediates.

When applying these methods, it's important to consider that some antibodies may not recognize all variants of MRPL7. For example, monoclonal antibodies targeting epitopes in the C-terminal region may fail to detect truncated variants like mrp7(1-187) and mrp7(1-146) .

What role does MRPL7 play in respiratory adaptation, and how can antibodies help study this function?

MRPL7 plays a crucial role in the adaptation from fermentative to respiratory metabolism, as evidenced by research on its mitospecific domain. Studies with truncated variants demonstrate that the C-terminal region of MRPL7 is particularly important for this adaptive response . Research has shown that:

• Strains with truncated MRPL7 (mrp7(1-187) and mrp7(1-146)) exhibit prolonged adaptation times when transitioning from glucose (fermentation) to glycerol/ethanol (respiratory) media .

• The C-terminal mitospecific domain appears to facilitate effective glucose derepression and respiratory adaptation.

• MRPL7 may influence the profile of mitochondrially synthesized proteins under different metabolic conditions, affecting the ratio of respiratory chain components.

MRPL7 antibodies can help study this function through:

• Time-course experiments: Monitoring MRPL7 levels and modifications during metabolic transitions using western blotting.

• Co-immunoprecipitation studies: Identifying MRPL7 interaction partners that change during metabolic adaptation.

• Chromatin immunoprecipitation: If MRPL7 has moonlighting functions involving nuclear DNA, as suggested for some mitoribosomal proteins.

• Pulse-labeling of mitochondrial translation products: Combined with MRPL7 immunoprecipitation to assess how MRPL7 variants affect synthesis of specific mitochondrial proteins during adaptation .

The difference in mitochondrial translation profiles observed between fermentation and respiration conditions, and how these are affected in MRPL7 mutants, provides a fascinating area for further investigation using antibody-based approaches .

How does the interaction between MRPL7 and MRPL12 affect mitochondrial translation, and what methods can be used to study this interaction?

The interaction between MRPL7 and MRPL12 forms a critical ribosomal stalk structure that is required for the recruitment of translation factors to the mitoribosome . This interaction is essential for efficient mitochondrial protein synthesis. To study this interaction and its effects on translation, researchers can employ several methodologies:

• Co-immunoprecipitation (Co-IP): Using antibodies against either MRPL7 or MRPL12 to pull down the protein complex and identify associated proteins. This approach can identify not only the direct interaction but also other proteins that may be part of the extended complex.

• Proximity labeling: Techniques such as BioID or APEX2 fused to either MRPL7 or MRPL12 can identify proteins in close proximity in living cells, providing a more physiological view of the interaction network.

• Förster Resonance Energy Transfer (FRET): By tagging MRPL7 and MRPL12 with appropriate fluorophores, researchers can detect direct interactions in living cells and determine how various conditions affect this interaction.

• Crosslinking coupled with mass spectrometry: This approach can identify specific residues involved in the MRPL7-MRPL12 interaction.

• Cryo-electron microscopy: Structural studies can reveal the precise arrangement of MRPL7 and MRPL12 within the mitoribosomal stalk and how this arrangement facilitates translation factor recruitment.

• In vitro translation assays: Using purified components to reconstitute translation systems with wild-type or mutant MRPL7/MRPL12 proteins can directly assess the functional consequences of the interaction.

Disruption of this interaction through mutation or depletion of either protein would be expected to reduce the efficiency of mitochondrial translation, particularly affecting the synthesis of respiratory chain components like Cox2 and cytochrome b .

What are the challenges in differentiating between specific and non-specific binding when using MRPL7 antibodies?

Differentiating between specific and non-specific binding is a significant challenge when working with MRPL7 antibodies, particularly due to several factors:

• Homology with other ribosomal proteins: MRPL7 shares structural similarities with other ribosomal proteins, which can lead to cross-reactivity. This is particularly problematic when distinguishing between mitochondrial and cytosolic ribosomal proteins.

• Multiple isoforms and post-translational modifications: MRPL7 may exist in different isoforms or with various post-translational modifications, which can affect antibody recognition and lead to multiple bands on western blots.

• Low abundance in whole cell lysates: Mitochondrial proteins are typically less abundant than cytosolic proteins, making specific detection challenging against background noise.

To overcome these challenges, researchers should employ multiple controls and validation strategies:

• MRPL7 knockdown/knockout controls: These provide the most definitive control for antibody specificity.

• Mitochondrial fractionation: Enriching for mitochondrial proteins can improve signal-to-noise ratio and help confirm mitochondrial localization.

• Peptide competition assays: Pre-incubating the antibody with the immunizing peptide should abolish specific signals.

• Multiple antibodies targeting different epitopes: Agreement between antibodies recognizing different regions of MRPL7 increases confidence in specificity.

• Recombinant protein standards: Using purified MRPL7 as a positive control can help identify the correct band size and antibody sensitivity.

When studying truncated variants of MRPL7, it's particularly important to verify that the antibody's epitope is preserved in the truncated protein. As observed in research with C-terminal truncations, some monoclonal antibodies may fail to recognize shorter variants if their epitope is in the deleted region .

How can MRPL7 antibodies be used to investigate mitochondrial disease models?

MRPL7 antibodies serve as valuable tools for investigating mitochondrial disease models through several methodological approaches:

• Assessment of mitoribosome integrity: In disease models with mitochondrial translation defects, MRPL7 antibodies can help evaluate whether mitoribosomal large subunit assembly is affected.

• Protein-protein interaction studies: Immunoprecipitation with MRPL7 antibodies can reveal altered interactions with other mitoribosomal proteins or translation factors in disease states.

• Tissue-specific expression analysis: MRPL7 antibodies can help determine if mitoribosomal components are differentially expressed in affected tissues in disease models.

• Response to stress conditions: By monitoring MRPL7 levels and localization after exposure to various stressors (oxidative stress, nutrient deprivation), researchers can assess how mitochondrial translation adapts in disease models.

• Therapeutic intervention studies: MRPL7 antibodies can help evaluate whether treatments restore normal mitoribosomal assembly and function.

The research on truncated MRPL7 variants provides a model for studying how mitoribosomal protein defects affect respiratory chain assembly. Studies showed that even when mitochondrial translation was largely maintained in MRPL7 mutants, there were specific defects in the assembly of complexes like COX and cytochrome bc1, while the F1F0-ATP synthase remained relatively unaffected . This selective impact on certain respiratory chain complexes mirrors findings in some mitochondrial diseases and provides insight into how translation defects can have complex downstream effects.

This table summarizes findings from studies with truncated MRPL7 variants, highlighting how antibody-based detection methods can reveal the complex relationships between mitoribosomal protein function and downstream mitochondrial activities .

What are the optimal fixation and permeabilization methods for immunofluorescence detection of MRPL7?

Optimal immunofluorescence detection of MRPL7 requires careful consideration of fixation and permeabilization methods to preserve both antigenicity and mitochondrial morphology. Based on research practices with mitochondrial ribosomal proteins, the following protocol is recommended:

These protocols should be optimized for specific cell types, as mitochondrial density and accessibility can vary significantly between different tissues and cell lines.

What experimental approaches can resolve contradictory results when using MRPL7 antibodies in different cell types?

When faced with contradictory results using MRPL7 antibodies across different cell types, researchers can employ several strategic approaches to resolve discrepancies:

• Comprehensive antibody validation in each cell type:

  • Perform MRPL7 knockdown or knockout controls specific to each cell type

  • Use multiple antibodies targeting different epitopes of MRPL7

  • Conduct peptide competition assays to confirm specificity

• Cell type-specific considerations:

  • Assess mitochondrial content differences between cell types (using mitochondrial mass markers)

  • Evaluate MRPL7 expression levels across cell types using qPCR

  • Consider cell type-specific post-translational modifications that might affect antibody recognition

• Technical optimization:

  • Adjust lysis conditions to account for differences in mitochondrial membrane composition

  • Optimize antibody concentration for each cell type

  • Consider native versus denaturing conditions for protein extraction

• Complementary approaches:

  • Use tagged MRPL7 expression to confirm antibody performance

  • Employ mass spectrometry to independently verify MRPL7 presence and modifications

  • Use CRISPR/Cas9 genome editing to introduce epitope tags into the endogenous MRPL7 locus

• Functional correlation:

  • Correlate antibody reactivity with functional readouts of mitochondrial translation

  • Assess respiratory complex assembly as a downstream indicator of MRPL7 function

A systematic approach using these methods can help determine whether contradictory results stem from technical issues with the antibody or represent genuine biological differences in MRPL7 expression, localization, or function between cell types. This is particularly important when studying cells with different metabolic profiles, as MRPL7 function appears to be closely linked to the balance between fermentative and respiratory metabolism .

What are the recommended protocols for co-immunoprecipitation using MRPL7 antibodies to study its interaction partners?

Co-immunoprecipitation (Co-IP) with MRPL7 antibodies requires careful protocol design to preserve native interactions while minimizing non-specific binding. The following detailed methodology is recommended for studying MRPL7 interaction partners:

• Cell lysis and mitochondrial isolation:

  • Isolate intact mitochondria using differential centrifugation

  • Lyse mitochondria in a gentle buffer containing 1% digitonin or 0.5-1% CHAPS to preserve ribosomal complexes

  • Typical buffer composition: 25 mM HEPES-KOH (pH 7.5), 5 mM MgCl2, 50 mM KCl, 1% detergent, protease inhibitor cocktail

• Pre-clearing step:

  • Incubate lysate with protein A/G beads for 1 hour at 4°C

  • Remove beads by centrifugation to reduce non-specific binding

• Antibody binding:

  • Incubate pre-cleared lysate with MRPL7 antibody (2-5 μg per mg of protein) overnight at 4°C with gentle rotation

  • For control samples, use non-immune IgG from the same species as the MRPL7 antibody

• Immunoprecipitation:

  • Add pre-washed protein A/G beads and incubate for 2-4 hours at 4°C

  • Wash beads 4-5 times with decreasing detergent concentrations (starting at 0.1%)

  • Include high-salt wash steps (150-300 mM KCl) to reduce non-specific interactions

• Elution options:

  • Competitive elution with MRPL7 peptide (when available)

  • Gentle elution with 0.1 M glycine (pH 2.5-3.0) followed by immediate neutralization

  • Direct elution in SDS sample buffer for subsequent SDS-PAGE analysis

• Analysis of co-precipitated proteins:

  • Western blotting for known or suspected interaction partners (e.g., MRPL12 )

  • Mass spectrometry for unbiased identification of the complete interactome

• Validation of interactions:

  • Reverse Co-IP using antibodies against identified partners

  • Proximity labeling techniques (BioID, APEX) as complementary approaches

  • In vitro binding assays with recombinant proteins

This protocol has been optimized to preserve the integrity of the mitoribosomal complex while allowing detection of both stable and transient interactions. The use of digitonin or CHAPS detergents is particularly important for maintaining the MRPL7-MRPL12 interaction that forms the ribosomal stalk structure essential for translation factor recruitment .

How can MRPL7 antibodies be used to study the effects of stress conditions on mitochondrial ribosome structure?

MRPL7 antibodies provide valuable tools for investigating how various stress conditions affect mitochondrial ribosome structure and function. Methodological approaches include:

• Stress response profiling:

  • Use MRPL7 antibodies in western blotting to monitor changes in mitoribosome composition under oxidative stress, nutrient deprivation, hypoxia, or drug treatments

  • Combine with Blue Native-PAGE to assess changes in intact ribosomal complex formation

  • Track degradation or modification of MRPL7 as an indicator of mitoribosomal stress

• Subcellular redistribution studies:

  • Employ immunofluorescence with MRPL7 antibodies to visualize changes in mitoribosomal localization during stress

  • Combine with markers of mitochondrial dynamics (fission/fusion proteins) to correlate with morphological changes

  • Use subcellular fractionation and western blotting to quantify redistribution between different mitochondrial compartments

• Interaction dynamics:

  • Perform co-immunoprecipitation with MRPL7 antibodies under normal and stress conditions to identify stress-induced changes in protein interactions

  • Focus particularly on the MRPL7-MRPL12 interaction, which is crucial for translation factor recruitment

• Translation activity correlation:

  • Correlate MRPL7 levels or modifications with mitochondrial translation activity using pulse-labeling of newly synthesized mitochondrial proteins

  • Examine whether stress-induced changes in MRPL7 predict shifts in translation profiles, similar to the observations in fermentation versus respiration conditions

• Adaptive responses:

  • Use MRPL7 antibodies to track recovery of mitoribosome assembly following removal of stress

  • Examine whether MRPL7 modifications persist during recovery phases

Research with truncated MRPL7 variants has shown that the C-terminal domain plays a crucial role in adaptation to respiratory metabolism . This suggests that MRPL7 may be particularly important during metabolic stress or transitions between energy production modes, making it an excellent target for studying mitochondrial adaptation to stress conditions.

What are the emerging applications of MRPL7 antibodies in understanding mitochondrial disease mechanisms?

MRPL7 antibodies are becoming increasingly valuable in unraveling mitochondrial disease mechanisms through several emerging applications:

• Biomarker development:

  • Analysis of MRPL7 levels or modifications in patient samples as potential diagnostic or prognostic markers for mitochondrial translation disorders

  • Correlation of MRPL7 status with clinical features and disease progression

• Pathogenic variant characterization:

  • Using antibodies to assess the impact of disease-associated variants on MRPL7 stability, localization, and incorporation into mitoribosomes

  • Comparing the effects of patient mutations to model systems like the truncated MRPL7 variants that showed respiratory defects

• Therapeutic monitoring:

  • Employing MRPL7 antibodies to track recovery of mitoribosome assembly following experimental treatments

  • Assessment of mitoribosomal adaptation in response to metabolic therapies

• Tissue-specific mitochondrial translation analysis:

  • Immunohistochemical detection of MRPL7 in tissues affected by mitochondrial disease

  • Correlation with tissue-specific pathology and respiratory chain defects

• Interaction with disease modifiers:

  • Investigation of how MRPL7 interacts with known mitochondrial disease modifiers

  • Study of how metabolic environment affects MRPL7 function in disease states

The observation that MRPL7 truncations specifically affect COX and cytochrome bc1 complex assembly while sparing F1F0-ATP synthase parallels findings in certain mitochondrial diseases. This selective impact suggests that MRPL7 may influence not only general mitochondrial translation but also the balance between different respiratory chain components, potentially explaining why some mitochondrial diseases preferentially affect certain complexes despite global translation defects.

These emerging applications highlight the potential of MRPL7 antibodies as both research tools and clinically relevant biomarkers in the study of mitochondrial diseases.